The geroscience hypothesis posits that common biological mechanisms of aging drive susceptibility of aged individuals to functional decline, multi-morbidity, and death. The promise of geroscience is that some of these mechanisms may be intervenable, thereby preventing or delaying declines, and providing new therapeutic opportunities for hard-to-treat chronic diseases. This is supported by specific examples of translational research models and interventions that are at the point of entering human clinical trials. This seminar will review how we are creating new translational frameworks to test the geroscience hypothesis. Specific examples will include evaluating biomarkers and interventions on cellular senescence, developing aging outcomes and feasible biomarker strategies for clinical trials testing pharmacologic and lifestyle interventions, and re-envisioning existing translational resources to accelerate the pace of geroscience.
Gross Hall, Room 270